Product News
Filter News
Found 274,410 articles
-
SaponiQx and InvivoGen Announce Agreement for SaponiQx to Supply Cultured Plant Cell QS-21 Adjuvant
4/17/2024
Agenus today announced an agreement to supply InvivoGen with STIMULON cultured plant cell (cpc) QS-21.
-
SCG Cell Therapy and A*STAR Launch Joint Labs With Collaboration Nearing S$30 Million to Advance iPSC Technology Towards Scalable GMP Manufacturing of Cellular Immunotherapies
4/17/2024
SCG Cell Therapy and the Agency for Science, Technology and Research announced the launch joint laboratories for cellular immunotherapies.
-
SOPHiA GENETICS Announces Unilabs is using its AI Technology to Detect Homologous Recombination Deficiency (HRD)
4/17/2024
SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, announced that Unilabs, one of the largest diagnostic providers in Europe, and the only provider to offer laboratory, imaging and pathology specialties within one group, is live on the SOPHiA DDM™ Platform.
-
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
4/17/2024
atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the publication of the Phase 1 results of BPL-003, Beckley Psytech’s novel, synthetic, intranasal benzoate salt formulation of 5-MeO-DMT, in The Journal of Psychopharmacology.
-
Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules
4/17/2024
Essential Pharma announces that it has completed the acquisition of Reminyl® oral capsules from Janssen Pharmaceutica NV, a Johnson & Johnson company.
-
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis
4/17/2024
Novartis announced data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta® treatment for up to six years in recently diagnosed – defined as starting treatment within three years of initial diagnosis – treatment-naïve people living with relapsing multiple sclerosis.
-
Cedar Clinical Research selected as clinical research site for Cybin's Phase 3 Study of CYB003
4/17/2024
Numinus Wellness Inc. is proud to announce that its research site, Cedar Clinical Research has been chosen as one of multiple sites for Cybin's Phase 3 pivotal, multinational clinical trial of CYB003 for the adjunctive treatment of Major Depressive Disorder ("MDD").
-
SyntheticMR and SimonMed Expand Trials of Synthetic MRI Testing and Announce Upcoming Expansion of Synthetic Availability from SyntheticMR's SyMRI NEURO Software at SimonMed Facilities
4/17/2024
SimonMed Imaging, one of the largest outpatient medical imaging providers and radiology practices in the United States, announces the continuation of its partnership with SyntheticMR for research as well as the upcoming expansion of synthetic availability from SyntheticMR's SyMRI NEURO software at its facilities.
-
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
4/17/2024
Sanofi’s CD40L antibody, frexalimab, demonstrated sustained reduction of disease activity and favorable tolerability after nearly one year in participants with relapsing multiple sclerosis.
-
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
4/17/2024
Genentech, a member of the Roche Group, announced data from the Phase III OCARINA II study of Ocrevus®, an investigational twice-yearly, 10-minute subcutaneous injection.
-
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
4/17/2024
BioCryst Pharmaceuticals, Inc. announced that the Brazilian Health Regulatory Agency has granted approval for oral, once-daily ORLADEYO® for the prophylaxis of hereditary angioedema attacks in adults and pediatric patients 12 years of age or older.
-
Pantheon Vision Announces Two Successful Pre-Submission Meetings With the FDA
4/17/2024
Pantheon Vision announced today the completion of two successful and productive Pre-Submission meetings with the U.S. Food and Drug Administration (FDA).
-
Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU Plan
4/17/2024
Nxera Pharma Co. Ltd announces that it has decided to issue new shares under the 19th to 22nd Restricted Stock Unit Plan and determined the payment amount and other matters of issuance of new shares under the 12th RSU and 14th RSU as follows.
-
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool
4/16/2024
Palisade Bio, Inc. announced today the successful completion of its analysis evaluating ex-vivo bioactivation of PALI-2108.
-
Sentynl Therapeutics Receives MHRA Authorization of NULIBRY® (fosdenopterin) for Treatment of MoCD Type A in Great Britain
4/16/2024
Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. (Zydus Group), today announced The Medicines and Healthcare products Regulatory Agency (MHRA) authorization of NULIBRY.
-
Propanc Biopharma Receives Certificate of Grant for “Composition of Proenzymes for Cancer Treatment” Patent from European Patent Office
4/16/2024
Propanc Biopharma, Inc. today announced that a certificate of grant for the Company’s “composition of proenzymes for cancer treatment,” patent was received from the European Patent Office.
-
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
4/16/2024
Petros Pharmaceuticals, Inc. announces it has received positive feedback from the U.S. Food and Drug Administration following the FDA's informal review of Petros' technology component for self-selection as the Company endeavors to achieve OTC status for STENDRA.
-
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
4/16/2024
PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced it has received an urgent request from the Ministry of Health (MOH) of Malawi, asking for emergency access to IV suramin to avert a potential humanitarian crisis brought on by dwindling supplies of drugs used routinely to save lives in that region of Africa.
-
Mabwell Releases Preclinical Study Results of Multiple Innovative Drugs Released at the 2024 AACR Annual Meeting
4/16/2024
Mabwell presented the preclinical research findings of three potential novel drug candidates in poster format at the American Association for Cancer Research (AACR) Annual Meeting, held from April 5 to 10, 2024.
-
NMDP BioTherapies Introduces Enhanced Cellular Materials for Allogeneic Cell Therapy Development
4/16/2024
NMDP BioTherapies ℠, formerly Be The Match BioTherapies unveiled substantial upgrades to its cellular starting material offerings, including incorporating a Drug Master File (DMF) with its rapid-delivery, standard GMP leukopak to simplify regulatory filings.